Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$27,000.00

Effect of the Aerobika Oscillating Positive Expiratory Pressure (OPEP) Device on Mucus Plugging and Airflow Obstruction in Patients with Moderate-to-severe Asthma

FY 2024-25

Summary
Mucus plugs play a critical role in asthma pathophysiology, contributing to airflow obstruction and adverse clinical outcomes. However, the impact of mucus on airflow obstruction remains largely unacknowledged in routine clinical practice and current management guidelines. Recently, Computed Tomography (CT) imaging of the lungs has emerged as an effective method to visualize mucus plugs in asthma. Dunican and colleagues were the first to describe the radiographic mucus score as a sum of bronchopulmonary segments with one or more mucus plugs visualized on lung CT scans. Current data suggests that mucus plugs are resistant, at least in part, to first-line asthma therapies. Mucus plugs persist over three years, despite treatment with high dose inhaled and oral corticosteroids. Additionally, biologic treatments for the management of asthma, including Benralizumab, Dupilumab and Tezepelumab, have been shown to improve, but not normalize the burden of mucus plugging in asthma. Airway clearance devices, such as the Aerobika Oscillating Positive Expiratory Pressure (OPEP) device, have demonstrated efficacy in mobilization of mucus secretions in patients with airways disease. To our knowledge, airway clearance devices have not been prospectively tested in moderate-to-severe asthma with, or without the addition of biologic therapy. In this two-center, randomized (1:1), open-label study of 30 adults with uncontrolled moderate-to-severe asthma (ACQ =1.5) and evidence of mucus plugging (CT mucus score = 4), we will investigate whether daily use of an Aerobika device for 16 weeks will decrease airway mucus (assessed by the CT mucus score). This will be associated with improved airway structure, airway function, and asthma control.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
530846
Name
Sandhu Ekamdeep S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Effect of the Aerobika Oscillating Positive Expiratory Pressure (OPEP) Device on Mucus Plugging and Airflow Obstruction in Patients with Moderate-to-severe Asthma
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Airway Clearance Therapy; Asthma; Computed Tomography (Ct); Magnetic Resonance Imaging (Mri); Mucus Plugging; Mucus Score; Oscillating Positive Expiratory Pressure (Opep)
Abstract
Mucus plugs play a critical role in asthma pathophysiology, contributing to airflow obstruction and adverse clinical outcomes. However, the impact of mucus on airflow obstruction remains largely unacknowledged in routine clinical practice and current management guidelines. Recently, Computed Tomography (CT) imaging of the lungs has emerged as an effective method to visualize mucus plugs in asthma. Dunican and colleagues were the first to describe the radiographic mucus score as a sum of bronchopulmonary segments with one or more mucus plugs visualized on lung CT scans. Current data suggests that mucus plugs are resistant, at least in part, to first-line asthma therapies. Mucus plugs persist over three years, despite treatment with high dose inhaled and oral corticosteroids. Additionally, biologic treatments for the management of asthma, including Benralizumab, Dupilumab and Tezepelumab, have been shown to improve, but not normalize the burden of mucus plugging in asthma. Airway clearance devices, such as the Aerobika Oscillating Positive Expiratory Pressure (OPEP) device, have demonstrated efficacy in mobilization of mucus secretions in patients with airways disease. To our knowledge, airway clearance devices have not been prospectively tested in moderate-to-severe asthma with, or without the addition of biologic therapy. In this two-center, randomized (1:1), open-label study of 30 adults with uncontrolled moderate-to-severe asthma (ACQ =1.5) and evidence of mucus plugging (CT mucus score = 4), we will investigate whether daily use of an Aerobika device for 16 weeks will decrease airway mucus (assessed by the CT mucus score). This will be associated with improved airway structure, airway function, and asthma control.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sandhu, Ekamdeep S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~